Gano Kyle Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
53
Insider Sells Sum
$44.65M

Insider Activity of Gano Kyle

According to the SEC Form 4 filings, Gano Kyle, being in a position of

  1. Chief Executive Officer at Neurocrine Biosciences, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 36700 shares for $4.87M,
    over all time since 2013-09-04, has bought 0 shares, and sold 582549 shares for $49.53M.

Biography of Gano Kyle

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $000
Sells
 $4,873,0492100

Comparison of Insiders on Amount of Buys and Sells

2026-01-16SaleNeurocrine Biosciences, Inc.
NBIX
Chief Executive Officer
36,400
0.0367%
$132.70$4.83M+9.92%
2025-11-04SaleNeurocrine Biosciences, Inc.
NBIX
Chief Executive Officer
300
0.0003%
$141.97$42,591+1.48%
2025-02-13SaleNeurocrine Biosciences, Inc.
NBIX
Chief Executive Officer
2,558
0.0025%
$116.85$298,908+14.2%
2025-02-10SaleNeurocrine Biosciences, Inc.
NBIX
Chief Executive Officer
980
0.0009%
$118.39$116,020+12.24%
2025-01-31SaleNeurocrine Biosciences, Inc.
NBIX
Chief Executive Officer
1,541
0.0015%
$152.87$235,577-12.38%
2025-01-15SaleNeurocrine Biosciences, Inc.
NBIX
Chief Executive Officer
65,000
0.0638%
$141.50$9.2M-6.54%
2024-02-13SaleNeurocrine Biosciences, Inc.
NBIX
Chief Business Development Off
1,352
0.0014%
$132.89$179,674+1.56%
2024-02-08SaleNeurocrine Biosciences, Inc.
NBIX
Chief Business Development Off
980
0.0009%
$134.20$131,519+1.15%
2024-02-06SaleNeurocrine Biosciences, Inc.
NBIX
Chief Business Development Off
1,600
0.0016%
$142.20$227,522-4.88%
2024-01-31SaleNeurocrine Biosciences, Inc.
NBIX
Chief Business Development Off
1,541
0.0016%
$140.70$216,813-2.7%
2024-01-02SaleNeurocrine Biosciences, Inc.
NBIX
Chief Business Development Off
75,000
0.0763%
$131.47$9.86M+2.72%
2023-08-21SaleNeurocrine Biosciences, Inc.
NBIX
Chief Business Development Off
2,132
0.0022%
$107.41$228,993+23.68%
2023-02-08SaleNeurocrine Biosciences, Inc.
NBIX
Chief Business Development Off
980
0.001%
$103.99$101,910+0.27%
2023-02-07SaleNeurocrine Biosciences, Inc.
NBIX
Chief Business Development Off
14,424
0.0147%
$102.40$1.48M+0.81%
2023-02-06SaleNeurocrine Biosciences, Inc.
NBIX
Chief Business Development Off
1,600
0.0017%
$105.64$169,028-0.44%
2023-01-31SaleNeurocrine Biosciences, Inc.
NBIX
Chief Business Development Off
1,541
0.0016%
$109.98$169,486-5.74%
2022-02-08SaleNeurocrine Biosciences, Inc.
NBIX
Chief Business Development Off
980
0.001%
$79.67$78,079+28.58%
2022-02-07SaleNeurocrine Biosciences, Inc.
NBIX
Chief Business Development Off
5,900
0.0062%
$80.77$476,549+26.82%
2022-01-05SaleNeurocrine Biosciences, Inc.
NBIX
Chief Business Development Off
28,266
0.0305%
$85.50$2.42M+16.88%
2021-02-08SaleNeurocrine Biosciences, Inc.
NBIX
Chief Business Development Off
3,693
0.0039%
$116.85$431,518-19.67%
Total: 55
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.